Trial Profile
A Phase Ib/II Study of PEP503 (Radioenhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Locally Advanced or Unresectable Rectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Hafnium oxide (Primary) ; Capecitabine; Fluorouracil
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PharmaEngine
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2022 Results presented in a Nanobiotix media release.
- 05 Jun 2022 According to Nanobiotix media release, data from the study were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.